Sacituzumab govitecan with or without atezolizumab for rare GU cancers
Treatments studied
Part of Cancer clinical trials.
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a rare type of genitourinary cancer that cannot be removed by surgery or has spread
- You need to have tumor tissue available from a previous biopsy, or agree to a new biopsy before starting
- Previous treatment history depends on which treatment group you would be in
- You must be able to get blood tests showing adequate organ function (kidney, liver, blood counts)
- You must not have certain medical conditions like active autoimmune disease or uncontrolled brain metastases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests sacituzumab govitecan, an anti-cancer drug, for people with urothelial (bladder/urinary tract) cancer that has spread or can’t be removed with surgery. It’s designed for tumors that have been treated already in specific ways, to see if the medicine can shrink or control the cancer.
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
This Phase 1 study tests whether a new bladder-cancer treatment plan—radiation given at the same time as sacituzumab govitecan—can help people with muscle-invasive bladder cancer without starting with traditional chemo/radiation. Because it’s early-stage, the main goal is safety and learning the best way to use this combination to preserve the bladder.
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
This trial tests a combination of two drugs—sacituzumab govitecan (targeted therapy) and capecitabine (chemotherapy)—for people with advanced stomach, colon, or pancreatic cancer that has stopped responding to standard treatments.
This trial tests a combination of two drugs, sacituzumab govitecan and zimberelimab, to treat muscle-invasive bladder cancer without removing the bladder. It's for patients who cannot or choose not to have bladder removal surgery or standard chemotherapy.
Hear when a new Renal Medullary Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.